Potent and broad antitumor effects of DX-8951f, a water-soluble camptothecin derivative, against various human tumors xenografted in nude mice

Cancer Chemotherapy and Pharmacology

Volumn 42, Issue 3, 1998, Pages 210-220

  Kumazawa, Eiji ^a   Jimbo, Takeshi ^a   Ochi, Yusuke ^a   Tohgo, Akiko ^a  

^a DAIICHI SANKYO CO   (Japan)

Author keywords

Camptothecin derivatives; CPT 11; DX 8951f; Human tumor xenografts

Indexed keywords

1 AMINO 9 ETHYL 5 FLUORO 2,3 DIHYDRO 9 HYDROXY 4 METHYL 1H,12H BENZO [DE]PYRANO [3',4':6,7]INDOLIZINO [1,2 B] QUINOLINE 10,13 (9H,15H) DIONE MONOMETHANESULFONATE DIHYDRATE; CAMPTOTHECIN DERIVATIVE; EXATECAN; GLYCOPROTEIN P; IRINOTECAN; LURTOTECAN; TOPOTECAN; UNCLASSIFIED DRUG;

ADOLESCENT; ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER; CANCER INHIBITION; COLON CANCER; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY CANCER; LUNG CANCER; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; CAMPTOTHECIN; COLONIC NEOPLASMS; HUMANS; KIDNEY NEOPLASMS; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASMS; STOMACH NEOPLASMS; SUBRENAL CAPSULE ASSAY; TUMOR CELLS, CULTURED;

EID: 0031869877     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050807     Document Type: Article

References (25)

1. Chen AY, Yu C, Potmesil M, Wall ME, Wani MC, Liu LF (1991) Camptothecin overcomes MDR1-mediated resistance in human KB carcinoma cells. Cancer Res 51: 6039
2. Chen C-J, Chin JE, Ueda K, Clark DP, Pastan I, Gottesman MM, Roninson IB (1986) Interna; duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell 47: 381
3. Emerson DL, Besterman JM, Brown HR, Evans MG, Leitner PP, Luzzio MJ, Shaffer JE, Sternbach DD, Uehling D, Vuong A (1995) In vivo antitumor activity of two new seven-substituted water-soluble camptothecin analogues. Cancer Res 55: 603
4. Fujita F, Fujita M, Taguchi T, Shimozuma K, Sakamoto Y, Kimoto Y, Hirai T (1989) Multifactorial analysis of parameters influencing chemosensitivity of human cancer xenografts in nude mice. Int J Cancer 43: 637
5. Fujita F, Fujita M, Fujita M, Sakamoto Y (1994) Combination chemotherapy of BOF-A2, a new 5-FU derivative, with various anticancer agents against human cancer xenografts in nude mice. Jpn J Cancer Chemother 21: 1619
6. Fukuoka M, Niitani H, Suzuki A, Motomiya M, Hasegawa K, Nishiwaki Y, Kuriyama T, Ariyoshi Y, Negoro S, Masuda N, Nakajima S, Taguchi T. the CPT-11 Lung Cancer Study Group (1992) A phase II study of CPT-II, a new derivative of camptothecin for previously untreated non-small-cell lung cancer. J Clin Oncol 10: 16
7. Gerlach JH, Endicott JA, Juranka PF, Henderson G, Sarangi F, Deuchars KL, Ling V (1986) Homology between P-glycoprotein and a bacterial haemolysin transport protein suggests a model for multidrug resistance. Nature 324: 485
8. Hendricks CB, Rowinsky EK, Grochow LB, Donehower RC, Kaufmann SH (1992) Effect of P-glycoprotein expression on the accumulation and cytotoxicity of Topotecan (SK&F 104864), a new camptothecin analogue. Cancer Res 52: 2268
9. Houghton PJ, Cheshire PJ, Myers L, Stewart CF, Synold TW, Houghton JA (1992) Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors. Cancer Chemother Pharmacol 31: 229
10. Joto N, Ishii M, Minami M, Kuga H, Mitsui I, Tohgo A (1997) DX-8951f, a water-soluble camptothecin analog, exhibits potent antitumor activity against a human lung cancer cell line and its SN-38-resistant variant. Int J Cancer 72: 680
11. Kang MC, Bankston DD, Erickson GA, Fang FG, Lackey JW, Lewis GS, Lichty ME, Lowery MW, Mader C, McDougald DL, Mook RA, Partrige JJ, Xie S (1991) Total synthesis of the novel water soluble camptothecin analog GI147211C, a potent topoisomerase I inhibitor (abstract). Proc Am Assoc Cancer Res 34: 332
12. Kanzawa F, Sugimoto Y, Minato K, Kasahara K, Bungo M, Nakagawa K, Fujiwara Y, Liu LF, Saijo N (1990) Establishment of a camptothecin analogue (CPT-11)-resistant cell line of human non-small cell lung cancer: characterization and mechanism of resistance. Cancer Res 50: 5919
13. Kawato Y, Aonuma M, Hirota Y, Kuga H, Sato K (1991) Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res 51: 4187
14. Kawato Y, Furuta T, Aonuma M, Yasuoka M, Yokokura T, Matsumoto K (1991) Antitumor activity of a camptothecin derivative, CPT-11, against human tumor xenografts in nude mice. Cancer Chemother Pharmacol 28: 192
15. Kingsbury WD, Boehm JC, Jakas DR, Holden KG, Hecht SM, Gallagher G, Caranfa MJ, McCabe FL, Faucette LF, Johnson RK, Hertzberg RP (1991) Synthesis of water-soluble (aminoalkyl) camptothecin analogues: inhibition of topoisomerase I and antitumor activity. J Med Chem 34: 98
16. Luzzio MJ, Besterman JM, Evans MG, Lackey KE, Leitner P, Peel MR, Sisco JM, Sternbach DD, Tong T, Uehling DE (1993) Novel water-soluble camptothecin analogs as inhibitors of topoisomerase I (abstract). Proc Am Assoc Cancer Res 34: 332
17. Masuda N, Fukuoka M, Kusunoki Y, Matsui K, Takifuji N, Kudoh S, Negoro S, Nishioka M, Nakagawa K, Takada M (1992) CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 10: 1225
18. Masuda N, Fukuoka M, Takada M, Kusunoki Y, Negoro S, Matsui K, Kudoh S, Takifuji M, Nakagawa K, Kishimoto S (1992) CPT-11 in combination with cisplatin for advanced non-small-cell lung cancer. J Clin Oncol 10: 1775
19. Mitsui I, Kumazawa E, Hirota Y, Aonuma M, Sugimori M, Ohsuki S, Uoto K, Ejima A, Terasawa H, Sato K (1995) A new water-soluble camptothecin derivative. DX-8951f. exhibits potent antitumor activity against human tumors in vitro and in vivo. Jpn J Cancer Res 86: 776
20. Negoro S, Fukuoka M, Niitani H, et al (1991) Phase II study of CPT-11, a new camptothecin derivative, in small cell lung cancer (SCLC) (abstract). Proc Am Soc Clin Oncol 10: 241
21. Shimada Y, Yoshino M, Wakui A, Nakao I, Futatsuki K, Sakata Y, Kambe M, Taguchi T, Ogawa N, the CPT-11 Gastrointestinal Cancer Study Group (1993) Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. J Clin Oncol 11: 909
22. Takeuchi S, Takamizawa H, Takeda Y, Okawa T, Tamaya T, Noda K, Sugawa T, Sekiba K, Yakushiji M, Taguchi T (1991) Clinical study of CPT-11, camptothecin derivative, on gynecological malignancy (abstract). Proc Am Soc Clin Oncol 10: 189
23. Takeuchi S, Noda K, Yakushiji M, et al (1992) Late phase II study of CPT-11, topoisomerase I inhibitor, in advanced cervical carcinoma (CC) (abstract). Proc Am Soc Clin Oncol 11: 224
24. Tsuji T, Kaneda N, Kada K, Yokokura T, Yoshimoto T, Tsuru D (1991) CPT-11 converting enzyme from rat serum: purification and some properties. J Pharmacobio-Dyn 14: 341
25. Tsuruo T (1988) Mechanism of multidrug resistance and implications for therapy. Jpn J Cancer Res 79: 285